SELL and neoplasm: Last but not least, it has been reported that reversible yet complete blockade of CAR tonic signaling during manufacture using dasatinib (67, 68), a Src-family kinase inhibitor suppressing the function of LCK/FYN (69) that transmits CAR activation signals from CD3ζ to downstream Syk-family kinases, resulted in GD2 CAR T cells enriched for the CD62L+CD45RO+ TCM subset, with lower expression of exhaustion markers including PD-1, TIM3, and LAG-3, as well as augmented in vivo function in a xenograft tumor model, compared to non-treated CAR T cells (70).